Woodline Partners’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Woodline Partners’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-375,000	Closed	-$3.79M	–	911
2022 Q4	$3.79M	Buy	375,000 +100,000	+36%	+$999K	0.05%	359
2022 Q3	$2.72M	Hold	275,000	–	–	0.04%	421
2022 Q2	$2.69M	Hold	275,000	–	–	0.04%	385
2022 Q1	$2.68M	Hold	275,000	–	–	0.04%	338
2021 Q4	$2.67M	Hold	275,000	–	–	0.04%	383
2021 Q3	$2.67M	Hold	275,000	–	–	0.04%	368
2021 Q2	$2.65M	Buy	+275,000	New	+$2.7M	0.05%	313

Woodline Partners's EBAC Position: Q1 2023 in Review

Woodline Partners sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 375,000 shares — an estimated $3.79M sold.

Woodline Partners first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $3.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Woodline Partners reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Woodline Partners sold 375,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $3.79M.
Woodline Partners first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Woodline Partners's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $3.79M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.